Caribou Biosciences (CRBU) Invested Capital (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Invested Capital data on file, last reported at $102.0 million in Q1 2026.

• Quarterly Invested Capital fell 53.04% year-over-year to $102.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.0 million (down 53.04% YoY) and the FY2025 annual result came in at $122.2 million, down 51.7% from the prior year.
• Invested Capital slipped to $102.0 million in Q1 2026 per CRBU's latest filing, from $122.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $398.3 million in Q3 2023 and bottomed at $102.0 million in Q1 2026.
• The 5-year median for Invested Capital is $281.2 million (2024), against an average of $270.4 million.
• The widest annual swing landed in 2022, when Invested Capital jumped 1141.77%; it then tumbled 53.04% in 2026.
• Tracing CRBU's Invested Capital over 5 years: stood at $300.9 million in 2022, then increased by 22.44% to $368.4 million in 2023, then plunged by 31.34% to $253.0 million in 2024, then slumped by 51.7% to $122.2 million in 2025, then dropped by 16.5% to $102.0 million in 2026.
• Per Business Quant, the three latest CRBU Invested Capital figures stand at $102.0 million (Q1 2026), $122.2 million (Q4 2025), and $141.8 million (Q3 2025).

Peer Comparison